Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy

Name: Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Published: 2009
License: Public Domain

Novartis Pharmaceuticals · 2009

ClinicalTrials.gov · Datasets · License: Public Domain · 2009

Open Source ↗

b-cells lymphoma

diffuse large b-cell lymphoma, diffuse large b cell lymphoma, dlbcl, poor risk, r-ipi 3-5, adjuvant therapy, after r-chop or r-epoch, after r-chop, b-cell lymphoma, lymphoma, b cells, blood cancer

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 860111
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.